May 2020 $5 M Private placement after listing $2 to $10 million 1
Oragenics Inc.: Private sale, May 2020 × Investors in this round 1 investor had bought by the notice of May 6, 2020: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice Alan Joslyn · Executive Officer, Director Michael Sullivan · Executive Officer Alan Dunton · Director Charles Pope · Director Frederick Telling · Director Robert Koski · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On a merger: “The consideration for the acquisition consisted of (i) $1,925,000 (less payment of certain liabilities), (ii) 9,200,000 shares of common stock; (iii) warrants to purchase 9,200,000 shares of common stock; and (iv) potential contingent consideration.”Signed by Michael Sullivan, Chief Financial Officer. Source: SEC Form D, newest notice filed May 6, 2020. Read the notice at the SEC .
equity, options SEC Apr 2018 $2 M Private placement after listing Under $2 million 2
Oragenics Inc.: Private sale, Apr 2018 × Investors in this round 2 investors had bought by the notice of Apr 12, 2018: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $144,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice Alan Joslyn · Executive Officer, Director Michael Sullivan · Executive Officer Alan Dunton · Director Charles Pope · Director Frederick Telling · Director Robert Koski · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round LADENBURG THALMANN & CO. INC. (CRD 505) · Miami, Florida Sold in NJ, NY Remarks in the notice On fees: “Sales commissions relates to commissions for the sale of common stock in the concurrent registered offering.”On the amounts: “The total offering amount includes the concurrent registered offering of common stock.”Signed by Michael Sullivan, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 12, 2018. Read the notice at the SEC .
equity, options SEC Nov 2017 $7 M Private placement after listing $2 to $10 million 5
Oragenics Inc.: Private sale, Nov 2017 × Investors in this round 5 investors had bought by the notice of Nov 14, 2017: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice Alan Joslyn · Executive Officer, Director Michael Sullivan · Executive Officer Alan Dunton · Director Charles Pope · Director Frederick Telling · Director Robert Koski · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Michael Sullivan, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 14, 2017. Read the notice at the SEC .
equity SEC May 2017 $1 M Private placement after listing Under $2 million 3
Oragenics Inc.: Private sale, May 2017 × Investors in this round 3 investors had bought by the notice of May 19, 2017: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $3 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice Alan Joslyn · Executive Officer, Director Michael Sullivan · Executive Officer Alan Dunton · Director Charles Pope · Director Frederick Telling · Director Robert Koski · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Michael Sullivan, Chief Financial Officer. Source: SEC Form D, newest notice filed May 19, 2017. Read the notice at the SEC .
equity SEC Jun 2016 $5 M Private placement after listing $2 to $10 million 3
Oragenics Inc.: Private sale, Jun 2016 × Investors in this round 3 investors had bought by the notice of Jul 13, 2016: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice Alan Joslyn · Executive Officer, Director Michael Sullivan · Executive Officer Alan Dunton · Director Charles Pope · Director Frederick Telling · Director Robert Koski · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Michael Sullivan, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 13, 2016. Read the notice at the SEC .
equity SEC Sep 2013 $10 M Private placement after listing $2 to $10 million 1
Oragenics Inc.: Private sale, Sep 2013 × Investors in this round 1 investor had bought by the notice of Oct 15, 2013: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity, debt Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice John Bonfiglio · Executive Officer, Director Michael Sullivan · Executive Officer Alan L. Dunton · Director Charles L. Pope · Director Christine Koski · Director Frederick W. Telling · Director Robert Koski · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The Company issued 1,300,000 shares to Intrexon Corporation in a private placement and 1,348,000 shares and note to Intrexon for a technology access fee in the amount of $1,956,000. Shares issued were based on a $3.00 per share price.”Signed by Michael Sullivan, Chief financial officer and treasurer. Source: SEC Form D, newest notice filed Oct 15, 2013. Read the notice at the SEC .
equity, debt SEC Jul 2012 $13 M No. 5 $10 to $50 million 53
Oragenics Inc.: Raise no. 5, Jul 2012 × Investors in this round 53 investors had bought by the notice of Aug 10, 2012: 53 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $13 M of $13 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions $899,698
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice John Bonfiglio · Executive Officer, Director Michael Sullivan · Executive Officer Alan L. Dunton · Director Charles L. Pope · Director Christine Koski · Director Frederick W. Telling · Director Robert Koski · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Griffin Securities, Inc. (CRD 43229) · New York, New York Sold in CT, FL, GA, MA, MD, NC, NJ, NY, OH, PA, TX, VA, VT, WY Remarks in the notice On fees: “In addition to cash fees, the Placement Agent received warrants to acquire an aggregate of 771,169 shares of common stock.”Signed by Michael Sullivan, Chief financial officer and treasurer. Source: SEC Form D and 1 amendment, newest notice filed Aug 10, 2012. Read the notice at the SEC .
equity SEC Jun 2012 $6 M No. 4 $2 to $10 million 1
Oragenics Inc.: Raise no. 4, Jun 2012 × Investors in this round 1 investor had bought by the notice of Jun 15, 2012: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice John Bonfiglio · Executive Officer, Director Michael Sullivan · Executive Officer Alan L. Dunton · Director Charles L. Pope · Director Christine Koski · Director Frederick W. Telling · Director Robert Koski · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The Company issued 4,392,425 common shares to Intrexon Corporation pursuant to an Exclusive Channel Collaboration Agreement. No cash was received. The amount entered is based solely on the closing price of the Company's stock of $1.32 on 6/5/2012.”Signed by Michael Sullivan, Chief financial officer and treasurer. Source: SEC Form D, newest notice filed Jun 15, 2012. Read the notice at the SEC .
equity SEC Mar 2012 $11 M No. 3 $10 to $50 million 1
Oragenics Inc.: Raise no. 3, Mar 2012 × Investors in this round 1 investor had bought by the notice of Apr 5, 2012: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $11 M of $11 M offered
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice John Bonfiglio · Executive Officer, Director Michael Sullivan · Executive Officer Alan L. Dunton · Director Charles L. Pope · Director Christine Koski · Director Frederick W. Telling · Director Robert Koski · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Company issued common stock and warrants in exchange for cancellation of $8,737,011 of indebtedness owed to the Koski Family Limited Partnership and a Note for up to $2.5 million in secured convertible debt.”Signed by Michael Sullivan, Chief financial officer and treasurer. Source: SEC Form D, newest notice filed Apr 5, 2012. Read the notice at the SEC .
equity, debt, options SEC Jul 2010 $2 M No. 2 $2 to $10 million 1
Oragenics Inc.: Raise no. 2, Jul 2010 × Investors in this round 1 investor had bought by the notice of Aug 11, 2010: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken $2,000,000
What was sold equity, debt
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice Brian Brian Bohunicky · Executive Officer David Brian Hirsch · Executive Officer, Director Jeffrey Brian Hillman · Executive Officer, Director Charles L. Pope · Director Christine Brian Koski · Director Frederick W. Telling · Director Robert Brian Koski · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by David Hirsch, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 11, 2010. Read the notice at the SEC .
equity, debt SEC Dec 2009 $3 M No. 1 $2 to $10 million 9
Oragenics Inc.: Raise no. 1, Dec 2009 × Investors in this round 9 investors had bought by the notice of Jan 13, 2010: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice Brian Brian Bohunicky · Executive Officer David Brian Hirsch · Executive Officer, Director Jeffrey Brian Hillman · Executive Officer, Director Christine Brian Koski · Director Robert Brian Koski · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Excludes $1,000,000 in offering of common stock in exchange for $1,000,000 outstanding secured debt which was condition of transaction.”On the use of proceeds: “While no proceeds were paid, we did issue shares to satisfy $54,062.50 owed to Chief Scientific Officer Jeff Hillman and $1.0M secured debt owed to the Koski FLP.”Signed by David Hirsch, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 13, 2010. Read the notice at the SEC .
equity SEC